logo
  

MRC Global Earnings Miss Estimates, Sees Tough Year Ahead; Stock Plunges 10%

MRC Global Inc (MRC), a distributor of pipes, valves and fittings to the energy industry, on Thursday reported fourth-quarter net earnings of $31.2 million or $0.30 per share compared with $23.3 million or $0.23 per share last year.

Excluding items, adjusted earnings for the quarter were $0.33 per share compared with $0.32 per share a year ago. Analysts polled by Thomson Reuters estimated earnings of $0.46 per share. Analysts' estimates typically exclude special items.

Revenues for the quarter were up 12.5% at $1.51 billion compared with $1.34 billion in the prior year. Analysts estimated revenues of $1.52 billion.

MRC's gross margin for the quarter fell to 16.4% from 16.8% last year.

For the full year 2015, MRC expects business conditions to be challenging. The company anticipates capital spending in North America to be down more than 35%, hurting its upstream business most directly, and to some extent, its midstream business as well. MRC said it would focus on cutting costs, reducing debt and optimizing working capital.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT